Literature DB >> 1982059

Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.

R Fogari1, A Zoppi, F Tettamanti, L Poletti, G Rizzardi, G Fiocchi.   

Abstract

The aim of the study was to compare the pulmonary effects of four beta-blockers with different ancillary properties: propranolol (non-beta 1 selective without ISA), oxprenolol (non-beta 1 selective with ISA), atenolol (beta 1 selective), and celipropol (beta 1 selective with mild beta 2-agonist and alpha 2-antagonist activity) in hypertensive patients with chronic obstructive lung disease. Ten asthmatic patients, all males, aged 50-66 years were studied. Entry criteria were a) DBP greater than or equal to 95 mmHg and less than or equal to 115 mmHg; b) FEV1 less than 70% of the theoretical values; c) FEV1 increase of at least 20% after salbutamol inhalation (200 micrograms). After a 2-week washout period on placebo, each patient received propranolol (80 mg/day), oxprenolol (80 mg/day), atenolol (100 mg/day), and celiprolol (200 mg/day) for 1 week, according to a randomized, cross-over design. At the end of the washout and of each treatment period, airway function, assessed by FEV1, FVC, and FEV1%, was evaluated by spirometry both in the basal condition and after salbutamol inhalation. Unlike propranolol and oxprenolol, which significantly reduced FEV1 and inhibited the bronchodilator response to inhaled salbutamol, atenolol and celiprolol did not significantly affect respiratory function and did not antagonize salbutamol effects. Celiprolol more closely approached placebo in its respiratory effects than did atenolol, although the differences were not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982059     DOI: 10.1007/bf01856511

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  33 in total

1.  Effects of high doses of celiprolol in asthmatic patients.

Authors:  H D Doshan; R Brown; W J Applin; M Kapoor; F S Caruso
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics.

Authors:  H Formgren
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

3.  A comparison of the effect on airway resistance of a new beta blocking drug, ICI.50,172 and propranolol.

Authors:  A G Macdonald; R S McNeill
Journal:  Br J Anaesth       Date:  1968-07       Impact factor: 9.166

4.  Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane.

Authors:  J M Raine; M G Palazzo; J H Kerr; P Sleight
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-14

5.  The cardiopulmonary effects of celiprolol and propranolol in asymptomatic bronchial asthmatics.

Authors:  H Matthys; M Pohl; H Braig; K H Rühle
Journal:  Br J Clin Pract Suppl       Date:  1985-06

6.  Celiprolol, clinical dosage, efficacy and safety in asthmatic and elderly patients.

Authors:  G Hitzenberger
Journal:  Br J Clin Pract Suppl       Date:  1985-06

7.  Bronchial response to beta-adrenergic blockade.

Authors:  G Zaid; G N Beall
Journal:  N Engl J Med       Date:  1966-09-15       Impact factor: 91.245

8.  Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease.

Authors:  J W Lammers; H T Folgering; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

9.  Effects of celiprolol on the bronchial reactivity in asthma.

Authors:  C Bruschi; L Casali; I Cerveri; V Peona; M C Zoia
Journal:  Am J Cardiol       Date:  1988-02-10       Impact factor: 2.778

10.  Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris.

Authors:  P Dorow; H Bethge; U Tönnesmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  15 in total

1.  Metoprolol has a similar therapeutic effect as amlodipine on BP lowering in hypertensive patients with obstructive sleep apnea.

Authors:  Jing Shi; Yue Yuan; Xianzhu Deng; Yujiao Pan; Meijiao He; Guangzhong Liu; Danghui Sun; Jiayu Wang; Wennan Wang; Yue Li
Journal:  Sleep Breath       Date:  2018-06-27       Impact factor: 2.816

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

4.  Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure.

Authors:  R J Shelton; A S Rigby; J G F Cleland; A L Clark
Journal:  Heart       Date:  2005-06-10       Impact factor: 5.994

Review 5.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 6.  Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.

Authors:  Michael Schivo; Timothy E Albertson; Angela Haczku; Nicholas J Kenyon; Amir A Zeki; Brooks T Kuhn; Samuel Louie; Mark V Avdalovic
Journal:  J Investig Med       Date:  2017-03-03       Impact factor: 2.895

Review 7.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 8.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 9.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 10.  Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.

Authors:  Khaled Albouaini; Mohammed Andron; Albert Alahmar; Mohaned Egred
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.